Short-term effects of intravitreal dexamethasone implant (OZURDEX®) on choroidal thickness in patients with naive branch retinal vein occlusion

ABSTRACT Purpose: The objective of this study was to evaluate subfoveal choroidal thickness (SFCT) using enhanced depth imaging optical coherence tomography (EDI-OCT) in patients with naïve branch retinal vein occlusion (BRVO) before and after intravitreal dexamethasone implant (Ozurdex®) injection. Methods: Thirty-nine patients with unilateral BRVO and 35 healthy subjects were included in this prospective study. Choroidal thickness was evaluated by EDI-OCT at baseline and 1 month after dexamethasone implant. Results: The mean SFCT measured in 39 patients with BRVO was 299.41 ± 55.86 µm, significantly greater than that in contralateral eyes (283.76 ± 57.44 µm; p=0.009) and control eyes (276.14 ± 39.06 µm; p=0.044). The mean SFCT after the treatment was 279.64 ± 50.96 µm, significantly thinner than that before intravitreal dexamethasone therapy (p=0.004). Conclusions: SFCT in treatment-naive BRVO eyes was significantly greater than that in contralateral eyes and healthy eyes and decreased significantly after intravitreal dexamethasone implantation.

摘要 目的：本研究旨在采用增强深度成像光学相干断层扫描（enhanced depth imaging optical coherence tomography，EDI-OCT），评估初治性分支视网膜静脉阻塞（branch retinal vein occlusion，BRVO）患者在接受玻璃体内地塞米松植入剂（intravitreal dexamethasone implant，Ozurdex®）注射前后的黄斑下脉络膜厚度（subfoveal choroidal thickness，SFCT）。方法：本前瞻性研究共纳入39例单侧BRVO患者及35名健康受试者。分别于基线期及地塞米松植入剂注射后1个月，采用EDI-OCT检测脉络膜厚度。结果：39例BRVO患者的平均黄斑下脉络膜厚度为299.41±55.86 μm，显著高于对侧眼（283.76±57.44 μm；p=0.009）及健康对照眼（276.14±39.06 μm；p=0.044）。治疗后平均黄斑下脉络膜厚度为279.64±50.96 μm，较玻璃体内地塞米松治疗前显著变薄（p=0.004）。结论：初治BRVO患眼的黄斑下脉络膜厚度显著高于对侧眼及健康眼，且在接受玻璃体内地塞米松植入术后显著降低。